@article {7522,
	title = {Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma},
	journal = {Haematologica},
	volume = {100},
	year = {2015},
	note = {Cited By :8Export Date: 21 February 2017},
	month = {2015},
	pages = {1334 - 1339},
	abstract = {Pomalidomide is a distinct oral IMiD{\textregistered} immunomodulatory agent with direct antimyeloma, stromal-support inhibitory, and immunomodulatory effects. The pivotal, multicenter, open-label, randomized phase 3 trial MM-003 compared pomalidomide + low-dose dexamethasone vs high-dose dexamethasone in 455 patients with refractory or relapsed and refractory multiple myeloma after failure of bortezomib and lenalidomide treatment. Initial results demonstrated significantly longer progression-free survival and overall survival with an acceptable tolerability profile for pomalidomide + low-dose dexamethasone vs high-dose dexamethasone. This secondary analysis describes patient outcomes by treatment history and depth of response. Pomalidomide + low-dose dexamethasone significantly prolonged progression-free survival and favored overall survival vs high-dose dexamethasone for all subgroups analyzed, regardless of prior treatments or refractory status. Both univariate and multivariate analyses showed that no variable relating to either the number (<= or > 3) or type of prior treatment was a significant predictor of progression-free survival or overall survival. No cross-resistance with prior lenalidomide or thalidomide treatment was observed. Patients achieving a minimal response or better to pomalidomide + low-dose dexamethasone treatment experienced a survival benefit, which was even higher in those achieving at least a partial response (17.2 and 19.9 months, respectively, as compared with 7.5 months for patients with less than minimal response). These data suggest that pomalidomide + low-dose dexamethasone should be considered a standard of care in patients with refractory or relapsed and refractory multiple myeloma regardless of prior treatment. ClinicalTrials.gov: NCT01311687; EudraCT: 2010-019820-30. {\textcopyright} 2015 Ferrata Storti Foundation.},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84943235900\&doi=10.3324\%2fhaematol.2015.125864\&partnerID=40\&md5=884d75796ce88e5bf968461186dccbdb},
	author = {San Miguel, J.F. and Weisel, K.C. and Song, K.W. and Delforge, M. and Karlin, L. and Goldschmidt, H. and Moreau, P. and Banos, A. and Oriol, A. and Garderet, L. and Cavo, M. and Ivanova, V. and Alegre, A. and Martinez-Lopez, J. and Chen, C. and Renner, C. and Bahlis, N.J. and Yu, X. and Teasdale, T. and Sternas, L. and Jacques, C. and Zaki, M.H. and Dimopoulos, M.A.}
}
